This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 56.3 kDa. The protein migrates as 56-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 6 months under sterile conditions after reconstitution.
Human CD19 (20-291), Fc Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized FMC63 at 1 μg/mL (100 μL/well) can bind Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259) with a linear range of 0.039-0.625 μg/mL (QC tested).
Immobilized Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259) at 5 μg/mL (100 μL/well) can bind FMC63 with a linear range of 0.6-20 ng/mL (QC tested).
Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259) captured on CM5 chip via Anti-Human lgG Fc antibodies surface can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 3.88 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
293 cells were transfected with FCM63-scFv and RFP tag. 2e5 of the cells were first incubated with A. Human Fc tag control. B. Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259, 10 μg/mL). C. Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259, 10 μg/mL) and FMC63 (Mouse anti-CD19 antibody). The FITC anti-human IgG Fc was used to analyse with FACS. RFP was used to evaluate CAR (FMC63-scFv) expression and FITC was used to evaluate the binding activity of Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259).
Human T cells were lentivirally transduced with anti-CD19 CAR and cultured for 3 days. Three days post-transduction, 1e6 cells were first incubated with 100 μL Human CD19 (20-291), Fc Tag, low endotoxin (Cat. No. CD9-H5259, 10 μg/mL), washed and then stained with PE anti-human IgG Fc Antibody. Non-transduced T cells were used as a control for gating of CAR expression. (Data are kindly provided by XIAMEN Anti-hela Biological TechnologyTrade Co. Ltd.)
Deep-learning based three-dimensional label-free tracking and analysis of immunological synapses of chimeric antigen receptor T cells. BioRxiv preprint. doi: https://www.biorxiv.org/content/10.1101/539858v1
Authors: M Lee, et al
Journal: BioRxiv 2019
Application: Flow cytometry
Authors: Hsu H, et al.
Journal: J Immunol 2018
Application: Granule mobilization assay
Authors: De Oliveira SN, et al.
Journal: J Transl Med 2013
Application: Flow cytometry
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.